Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01457781 is registered in ClinicalTrials.gov with Bellerophon Pulse Technologies as lead sponsor.

NCT NCT01457781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01457781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Bellerophon Pulse Technologies
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
July 31, 2016
Enrollment
80 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension, pulmonary hypertension